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Figure 1. Anti-inﬂammatory cytokine concentrations.* signiﬁcantly < APS
Device System (p<0.05, t-test).
Figure 2. Anabolic growth factor concentrations.* signiﬁcantly < APS
Device System (p< 0.05, t-test).
Abstracts / Osteoarthritis and Cartilage 22 (2014) S57–S489S484cartilage degradation and conﬁrms a link between a native biological
pathway and pharmacology which translates to human tissues and
non-human primate models, subsequently pointing to a speciﬁc OA
patient population to target. However, our results suggest selective and
potent ADAMTS-5 engagement/inhibition with GSK2394002, while
demonstrating desired effects on cartilage-related endpoints, results in
modulation of CV functions that pose considerable challenges for clin-
ical development.
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COMPARISON OF THE CELLULAR AND CYTOKINE CONCENTRATIONS
IN THE OUTPUT OF THE AUTOLOGOUS PROTEIN SOLUTION,
ORTHOKINE, AND ONOCCOMED 2 DEVICE SYSTEMS
W. King, J. Woodell-May. Biomet, Warsaw, IN, USA
Purpose: The purpose of this study was to characterize the cellular and
cytokine concentrations in the outputs of the Autologous Protein Sol-
ution (APS), Orthokine, and Onoccomed 2 Device Systems. Anti-
inﬂammatory cytokines and anabolic growth factors were analyzed due
to their potential role in inhibiting damaging inﬂammation in osteo-
arthritis (OA) and inducing disease-modifying cartilage repair.
Methods: Blood from 6 human donors (WIRB Study # 1115097) was
drawn and allocated so that blood from each donor was used for 1)
whole blood analysis, 2) processing with the APS Device System (Bio-
met, Warsaw, IN, USA), 3) Orthokine Device System (Orthogen Lab
Services, Dusseldorf, Germany), and the Onoccomed 2 Device System
(Plasmaconcept AG, Bonn, Germany). Each device systemwas processed
according to the manufacturer’s instructions. Cellular content was
analyzed using a Cell Dyn 3700 hematology analyzer (Abbott Labo-
ratories, Chicago, IL, USA). Cytokine content was measured using
enzyme-linked immunosorbent assays (R&D Systems, Minneapolis,
MN, USA).
Results: The APS Device System produced a solution with greater
concentrations of white blood cells (WBC) and platelets (PLT) than
whole blood, the output of the Orthokine Device System, and the
Onoccomed 2 Device System (p < 0.05, t-test). The output of the APS
Device System contained signiﬁcantly decreased red blood cell (RBC)
concentrations than whole blood, but greater than the RBC concen-
trations in the conditioned serums produced by the Orthokine and
Onoccomed 2 Device Systems (p < 0.05, t-test) (Table 1).
The APS Device System produced solutions with signiﬁcantly greater
concentrations of anti-inﬂammatory cytokines than the Orthokine and
Onoccomed 2 device systems (Figure 1). For example, the concentration
of interleukin-1 receptor antagonist (IL-1ra) in the output of the APS
device system was 54,922.1  32,750.7 (pg/ml), whereas the output of
the Orthokine device systemwas 1,618.0 674.7 (pg/ml) and the output
of the Onoccomed 2 device system was 277.1  338.2 (pg/ml). The
concentration of IL-1ra in the outputs of the Orthokine and Onoccomed
2 device systems were signiﬁcantly less than the IL-1ra concentration in
whole blood (5664.5  2,317.6 pg/ml) (p < 0.05). The output of the APS
device system also contained signiﬁcantly greater concentrations of
soluble interleukin-1 receptor antagonist type II (sIL-1RII), soluble
tumor necrosis factor type I (sTNF-RI), and sTNFR-II (p < 0.05, t-test)
(Figure 1).
The APS Device System produced solutions with similar or signiﬁcantly
greater concentrations of anabolic growth factors compared to the
other device systems. For example, the APS Device System produced a
solution that contained 13,575.9  5,959.2 (pg/ml) platelet-derived
growth factor-BB (PDGF-BB). The Onoccomed 2 and Orthokine device
systems had outputs containing 2,302.3  1,022.6 and 2,765.5  1,101.2
(pg/ml) PDGF-BB, respectively (p < 0.05, t-test). The APS Device System
also produced solutions with signiﬁcantly greater concentrations of
PDGF-AB, transforming growth factor-b (TGF-b), and epidermal growth
factor (EGF) compared to the Onoccomed 2 Device System (p < 0.05, t-Table 1
Concentration of white blood cells (WBC) (k/ml), Platelets (k/ml), and red blood cells
(RBC) (M/ml)
WBC (k/ml) PLT (k/ml) RBC (M/ml)
Whole blood 5.4  1.8 175.1  69.5 5.5  1.1
APS 46.5  19.9 1184.4  556.4 1.4  1.5
Orthokine 0.0  0.0 13.5  5.5 0.0  0.0
Onoccomed 2 0.0  0.0 11.4  1.7 0.0  0.0test). There were no signiﬁcant differences in the concentrations of EGF,
insulin-like growth factor-1 (IGF-1), and TGF-b in the outputs of the APS
and Orthokine device systems. However, the APS Device System pro-
duced solutions with signiﬁcantly greater concentrations of PDGF-AB
and PDGF-BB than the Orthokine Device System (p < 0.05, t-test).
Conclusions: The APS device system produced solutions with sig-
niﬁcantly greater concentrations of anti-inﬂammatory cytokines and
similar or greater concentrations of anabolic growth factors than the
Orthokine or Onoccomed 2 Device Systems. Signiﬁcantly, the average
IL-1ra concentration in the output of the APS Device system was 34X
that of the Orthokine Device System and 198X that of the Onoccomed 2
Device System from the same donors. The cytokine proﬁle of APS can be
attributed to its increased concentrations of WBC and platelets com-
pared to the acellular conditioned serums.
Tissue Engineering
885
DEVELOPMENT OF GROWTH FACTOR TETHERED HYALURONAN
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